Product name: Dabigatran etexilate mesylate
CAS: 872728-81-9
Assay: ≥98.5%
MF: C34H41N7O5.CH4O3S C8H15NO2
Appearance: White to off-white solid
Melting Point: 178~183°C
Dabigatran Etexilate Mesylate powder cas 872728-81-9 is used to prevent stroke and harmful blood clots (such as in your legs or lungs) if you have a certain type of irregular heartbeat (atrial fibrillation).
*The following content is generated by AI and is for reference only.
Dabigatran etexilate mesylate powder is a high-purity pharmaceutical intermediate and active research compound widely utilized in biomedical studies. Chemically, it serves as the prodrug form of dabigatran, a potent direct thrombin inhibitor. The molecular formula for Dabigatran etexilate mesylate is typically represented as C21H30N6O5·CH4O3S, reflecting the combination of the base molecule with methanesulfonic acid to enhance stability and solubility for laboratory applications. Its corresponding CAS registry number is 84397-55-3, a unique identifier essential for precise chemical sourcing and regulatory compliance.
This substance acts as a critical tool in cardiovascular pharmacology research. As a prodrug, it is rapidly converted by esterases into its active metabolite, dabigatran etexilate, which directly binds to the active site of thrombin. By inhibiting thrombin, it effectively prevents the conversion of fibrinogen to fibrin, thereby blocking blood clot formation. Consequently, this compound is extensively employed in vitro and in vivo models to investigate mechanisms of thrombosis, evaluate novel anticoagulant therapies, and validate assay methodologies for hemostasis. Researchers utilize the mesylate salt form due to its improved physicochemical properties compared to the free base, ensuring consistent results in drug discovery pipelines.
In clinical contexts, the active moiety derived from this powder forms the basis of approved oral anticoagulants used to reduce stroke risk in patients with non-valvular atrial fibrillation and to treat venous thromboembolism. However, in the context of this specific powder product, it is primarily intended for research and development purposes within academic institutions, pharmaceutical companies, and diagnostic laboratories. Strict adherence to safety protocols is mandatory when handling this material, as it possesses significant biological activity. Users must ensure proper storage conditions to maintain potency and prevent degradation. This compound remains a cornerstone in the advancement of safer, more effective antithrombotic treatments, offering valuable insights into coagulation pathways and facilitating the development of next-generation therapeutics for managing blood disorders globally.